Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

The pharmacokinetics, metabolism, and excretion of dolutegravir, an unboosted, once-daily human immunodeficiency virus type 1 integrase inhibitor, were studied in healthy male subjects following single oral administration of [(14)C]dolutegravir at a dose of 20 mg (80 μCi). Dolutegravir was well tole...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Castellino, Stephen, Moss, Lee, Wagner, David, Borland, Julie, Song, Ivy, Chen, Shuguang, Lou, Yu, Min, Sherene S., Goljer, Igor, Culp, Amanda, Piscitelli, Stephen C., Savina, Paul M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2013
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3719771/
https://ncbi.nlm.nih.gov/pubmed/23669385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00292-13
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados